Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMN-006
- Development stage
- Preclinical
- Lead developer
- CoImmune
- Modality
- Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CMN-006 is an allogeneic chimeric antigen receptor-modified cytokine-induced killer (CAR-CIK) cell therapy targeting CD19, currently in preclinical development for the treatment of acute myeloid leukemia (AML). Developed by CoImmune (now Benecyte), the therapy utilizes a proprietary non-viral Sleeping Beauty gene transfer technology to genetically modify CIK cells. CIK cells are a unique population of cytotoxic lymphocytes that combine the phenotypic and functional properties of both T-cells and natural killer (NK) cells. This platform is designed to offer enhanced anti-tumor efficacy with a reduced risk of graft-versus-host disease (GVHD) compared to traditional CAR-T therapies, as CIK cells possess innate killing mechanisms while resisting the induction of GVHD in an allogeneic setting.
- Other names
- CD19-CAR-CIK cell therapyCD-19-CAR-CIK cell therapyCD 19-CAR-CIK cell therapy
02
Targets
Beyond the preview
Go deeper on CMN-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMN-006.